Eli Lilly and Company $LLY Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 0.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 51,328,908 shares of the company’s stock after selling 4,312 shares during the period. Eli Lilly and Company makes up 27.3% of PNC Financial Services Group Inc.’s holdings, making the stock its biggest holding. PNC Financial Services Group Inc. owned 0.05% of Eli Lilly and Company worth $47,210,789,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Oslo Pensjonsforsikring AS acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $2,733,000. HORAN Wealth LLC raised its holdings in shares of Eli Lilly and Company by 1.9% during the 1st quarter. HORAN Wealth LLC now owns 824 shares of the company’s stock worth $758,000 after buying an additional 15 shares in the last quarter. DJE Kapital AG bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $234,543,000. Andra AP fonden boosted its stake in Eli Lilly and Company by 52.9% in the first quarter. Andra AP fonden now owns 127,233 shares of the company’s stock valued at $117,025,000 after buying an additional 44,003 shares in the last quarter. Finally, Wilkerson Advisory Group LLC grew its position in Eli Lilly and Company by 18.9% in the first quarter. Wilkerson Advisory Group LLC now owns 1,454 shares of the company’s stock valued at $1,337,000 after acquiring an additional 231 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on LLY. Royal Bank Of Canada raised their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Sanford C. Bernstein boosted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. Finally, Bank of America increased their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several market commentary pieces highlighted Lilly’s leadership in GLP-1 obesity treatments, its expanding pipeline, and the view that its growth outlook remains strong despite intensifying competition from Novo Nordisk.
• Positive Sentiment: Analyst-focused coverage continued to point to Lilly’s momentum from Zepbound and Mounjaro, with investors still treating the company as a core winner in the fast-growing weight-loss and diabetes market.
• Positive Sentiment: Broader healthcare stocks also moved higher, which likely provided a supportive backdrop for Eli Lilly shares during the session.
• Neutral Sentiment: Eli Lilly defended its advertising, saying its comparisons are based on the SURMOUNT-5 trial, while noting Novo’s criticism centers on the use of older dose comparisons rather than direct head-to-head data.
• Negative Sentiment: Novo Nordisk sued Eli Lilly in U.S. federal court, accusing the company of false and misleading advertising for Zepbound and Mounjaro and seeking to stop the ads, force corrective marketing, and recover damages. Reuters article about the lawsuit

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,175.15 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The business’s 50 day simple moving average is $1,126.19 and its 200 day simple moving average is $1,037.68. The stock has a market capitalization of $1.11 trillion, a PE ratio of 41.75, a PEG ratio of 1.44 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the company earned $3.34 EPS. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 34.55 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.